Peter Xia

➢ Provided regional field medical leadership through credible scientific engagement with key opinion leaders in the Ontario and Atlantic regions, including support for both our established portfolio and investigational drugs. ➢ Supported portfolio of 8 products across multiple therapeutic areas, including topical products and a specialty biologic. ➢ Executed consultancy meetings/advisory boards/conference symposia/ambassador programs to drive medical strategy and educate HCP community. ➢ Led market access advocacy efforts amongst clinicians for HTA bodies and provincial negotiations. Recognition ➢ Performance Mindset in recognition of agility and ability to think outside-the-box, to advance business objectives beyond my role, team, and department. ➢ Enterprise Mindset in recognition of strong collaborative efforts.

Industrial Pharmacy Residency in Market Access ➢ One of 17 residents (and only market access resident) in 2018-2019 year, from amongst 250+ candidates across Canada and US. SPINRAZA® Market Access & pCPA Negotiations ➢ Conducted key budget impact analyses and businesses cases for pCPA and private payer negotiations, including planning for several outcomes based on CADTH recommendations for SPINRAZA®, the first treatment in spinal muscular atrophy (SMA). ➢ Project lead to guide 5 separate teams: key account managers, PSP managers, medical science liaisons, government relations team, and the finance team, with their ad-hoc analyses of SPINRAZA access and treatment ➢ Utilize strength in data analysis by creating and maintaining a central dashboard used by all members of the spinal muscular atrophy (SMA) team to inform key business decisions, including senior leadership. ➢ Overall, manage communication between large cross-functional team, vastly increase efficiency of data analytics within the organization, and regularly report the state of our SMA business directly to senior leadership. Awards ➢ Biogen BIG Award for “Agility” in recognition of my efforts with SMA project management and for the creation of a SMA dashboard, used across the organization and by senior leadership for business insights and reporting. ➢ Biogen Excellence in Pioneering Award to the market access team for groundbreaking pCPA negotiations for SPINRAZA®, a $750,000/yr drug, while accounting for many outcomes amid CADTH resubmissions.

➢ After completing my 5-week advanced pharmacy placement at ClaimSecure, I was invited back to continue in my role with assessing special authorization claims in a paid role.

➢ Using CADTH pharmacoeconomic and clinical reports, assessed budget impact implications of adding new drugs onto the ClaimSecure formularies, including IZBA, IBRANCE, and XOLAIR. ➢ Created the Maviret Drug Review – published online by ClaimSecure on February 2018 – to educate plan members and sponsors on the disease background, drug details, and financial impact. ➢ Performed therapeutic class reviews to recommended criteria modernization to senior leadership. ➢ Evaluated special authorizations and notified patients of the outcome. With claims and medication history, arrived at a coverage decision on a case-by-case basis using coverage criteria, therapeutic knowledge, and consideration of patient outcomes.